View Older Stories View More Recent Stories
-
Abivax (ABVX) PT Raised to $187 at Citizens
-
Jefferies Downgrades Abivax (ABVX) to Hold
-
After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
-
Abivax (ABVX) Halted, News Pending
-
Abivax (ABVX) Reiterated at Market Outperform by Citizens on Open-label Results
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Abivax files annual reports with French and US regulators
-
Abivax (ABVX) remains 'Best Idea' at Guggenheim following FY25 update
-
Truist on Abivax (ABVX): 'We continue to see a robust opportunity'
-
Abivax (ABVX) Reiterated at Market Outperform by Citizens Ahead of ABTECT-UC Results
-
Jefferies says these are the best SMID-cap biotech stocks to buy
-
Piper Sandler on Abivax (ABVX): 'We Remain Buyers'
-
Jefferies Starts Abivax (ABVX) at Buy
-
Wedbush Starts Abivax (ABVX) at Underperform
-
Abivax (ABVX) Reiterated at Market Outperform by Citizens: Presented 22 Abstracts
-
Guggenheim Reiterates Abivax (ABVX) at Buy, 'ABVX remains as our Best Idea'
-
Abivax shares trim gains after French Finance Ministry statement
-
Abivax shares surge after report flags continued Eli Lilly takeover interest
-
Abivax (ABVX) Reiterated at Market Outperform by Citizens: Has Cash Runway into 4Q27
-
Abivax (ABVX) PT Raised to $150 at BTIG
-
Leerink Partners on Abivax (ABVX): 'Key Clinical & Regulatory Catalysts on Track'
-
Abivax soars on report of Eli Lilly meeting French officials over possible deal
-
Abivax secures 22 abstracts on inflammatory bowel disease drug at ECCO 2026
-
Abivax (ABVX) Cash Position Supports Obefazimod Development - Citizens
-
Truist Securities Starts Abivax (ABVX) at Buy
-
Citizens Reiterates Abivax (ABVX) at Market Outperform After Phase 3 ABTECT Study
-
Barclays Starts Abivax (ABVX) at Overweight
-
Abivax (ABVX) PT Raised to $150 at Guggenheim, named 'Best Idea'
-
Abivax (ABVX) PT Raised to $115 at Leerink Partners
-
Abivax presents ulcerative colitis drug data at gastroenterology meeting
-
Citizens Reiterates Market Outperform Rating on Abivax (ABVX)
-
Abivax (ABVX) PT Raised to $114 at Citizens JMP
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Guggenheim on Abivax (ABVX): 'We expect ABVX to get a late-breaker and/or a plenary session at the UEGW'
-
Abivax (ABVX) PT Raised to $112 as Piper Sandler 'Continues to See Upside'
-
Abivax launches $400 million public offering of American depositary shares
-
Abivax (ABVX) PT Raised as Piper Sandler 'Remain Buyers'
-
Morgan Stanley Upgrades Abivax (ABVX) to Overweight
-
Abivax (ABVX) PT Raised to $74 at Leerink Partners
-
Abivax (ABVX) PT Raised to $101 at Guggenheim
-
Abivax (ABVX) PT Raised to $95 at Citizens JMP
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Piper Sandler Sees an 'Attractive Risk/Reward' on Abivax (ABVX) Shares
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Abivax (ABVX) Appoints Dominik Höchli to its Board
-
Guggenheim Reiterates Buy Rating on Abivax (ABVX), PT $50
-
BTIG Reiterates Buy Rating on Abivax (ABVX)
-
Morgan Stanley Assumes Abivax (ABVX) at Equalweight

